Mathieu Romain, Arango Juan David Ospina, Beckendorf Véronique, Delobel Jean-Bernard, Messai Taha, Chira Ciprian, Bossi Alberto, Le Prisé Elisabeth, Guerif Stéphane, Simon Jean-Marc, Dubray Bernard, Zhu Jian, Lagrange Jean-Léon, Pommier Pascal, Gnep Khemara, Acosta Oscar, De Crevoisier Renaud
Department of Urology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France,
World J Urol. 2014 Jun;32(3):743-51. doi: 10.1007/s00345-013-1146-8. Epub 2013 Aug 29.
To analyze late urinary toxicity after prostate cancer radiotherapy (RT): symptom description and identification of patient characteristics or treatment parameters allowing for the generation of nomograms.
Nine hundred and sixty-five patients underwent RT in seventeen French centers for localized prostate cancer. Median total dose was 70 Gy (range, 65-80 Gy), using different fractionations (2 or 2.5 Gy/day) and techniques. Late urinary toxicity and the corresponding symptoms (urinary frequency, incontinence, dysuria/decreased stream, and hematuria) were prospectively assessed in half of the patients using the LENT-SOMA classification. Univariate and multivariate Cox regression models addressed patient or treatment-related predictors of late urinary toxicity (≥grade 2). Nomograms were built up, and their performance was assessed.
The median follow-up was 61 months. The 5-year (≥grade 2) global urinary toxicity, urinary frequency, hematuria, dysuria, and urinary incontinence rates were 15, 10, 5, 3 and 1 %, respectively. The 5-year (≥grade 3) urinary toxicity rate was 3 %. The following parameters significantly increased the 5-year risk of global urinary toxicity (≥grade 2): anticoagulant treatment (RR = 2.35), total dose (RR = 1.09), and age (RR = 1.06). Urinary frequency was increased by the total dose (RR = 1.07) and diabetes (RR = 4). Hematuria was increased by anticoagulant treatment (RR = 2.9). Dysuria was increased by the total dose (RR = 1.1). Corresponding nomograms and their calibration plots were generated. Nomogram performance should be validated with external data.
The first nomograms to predict late urinary toxicity but also specific urinary symptoms after prostate RT were generated, contributing to prostate cancer treatment decision.
分析前列腺癌放疗(RT)后的晚期泌尿系统毒性:症状描述以及确定可用于生成列线图的患者特征或治疗参数。
17个法国中心的965例患者接受了局限性前列腺癌的放疗。中位总剂量为70 Gy(范围65 - 80 Gy),采用不同的分割方式(2或2.5 Gy/天)和技术。使用LENT - SOMA分类法对半数患者前瞻性评估晚期泌尿系统毒性及相应症状(尿频、尿失禁、排尿困难/尿流减弱和血尿)。单因素和多因素Cox回归模型分析患者或治疗相关的晚期泌尿系统毒性(≥2级)预测因素。构建列线图并评估其性能。
中位随访时间为61个月。5年(≥2级)总体泌尿系统毒性、尿频、血尿、排尿困难和尿失禁发生率分别为15%、10%、5%、3%和1%。5年(≥3级)泌尿系统毒性发生率为3%。以下参数显著增加了5年总体泌尿系统毒性(≥2级)风险:抗凝治疗(RR = 2.35)、总剂量(RR = 1.09)和年龄(RR = 1.06)。尿频受总剂量(RR = 1.07)和糖尿病(RR = 4)影响而增加。血尿因抗凝治疗(RR = 2.9)而增加。排尿困难受总剂量(RR = 1.1)影响而增加。生成了相应的列线图及其校准图。列线图性能需用外部数据验证。
生成了首个预测前列腺癌放疗后晚期泌尿系统毒性以及特定泌尿系统症状的列线图,有助于前列腺癌治疗决策。